Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.10), $0.09 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $38.2 million versus the consensus estimate of $39.49 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.